Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - June 2013


Advanced Portfolio Management for the Pharma and Biotech Industries

10 Jun 2013 - 12 Jun 2013 - Zurich, Switzerland



Bookmark and Share


In an era of declining R&D productivity and unprecedented loss of blockbuster patent exclusivity, the need to maximize the value of its core assets under ever constrained budgetary and human resources has never been more critical to the Pharmaceutical and Biotechnology industry. An integral part of strategic and business planning, the portfolio management process influences decisions that directly impact company fortunes — especially when advancing the right compounds under risk and uncertainty to create the potential for billions of dollars in long-term revenue.

Effective portfolio management requires foresight, discipline, preparation, and diligence, a serious challenge given the daily pressures faced by all organizations. Top-performing companies review, refresh, and execute their portfolio strategies on a continual basis through the application of excellent process, methodology, analysis, and decision making. For many organizations, however, numerous obstacles make it difficult to adopt a sustainably successful approach to portfolio management.

This Masterclass is your roadmap to maximizing portfolio value in accordance with management’s strategic and financial goals. Designed to improve companies’ abilities to progress compounds from the pre-clinical stage to commercial brand management, it showcases benchmarks and best practices for teams managing investments across the entire value chain – pre-clinical and clinical projects as well as marketed brand products.

The Masterclass will introduce the CREOPM™ Methodology, a unique, holistic framework for Portfolio Management developed by the trainer – Dr. Richard Bayney – President of Project & Portfolio Value Creation. Dr. Bayney, a 23-year veteran of the Pharmaceutical and Biotechnology industry, was Head of Strategic Planning at Bayer and Head of Portfolio Management & Decision Analysis at Bristol-Myers Squibb and Johnson & Johnson. CREOPM™ is an overarching Portfolio Management framework comprised of the following steps:

  • Categorize
  • Risk Analysis
  • Evaluate
  • Optimize
  • Prioritize
  • Manage

 

Reinforce your portfolio management strategy and enable execution with the CREOPM™ framework

Follow a step-by-step guide to improve strategic planning, create the criteria necessary to advance some projects while discontinuing others, and make the best use of constrained budgetary and human resources by maximizing strategic and financial value. Understand team members’ roles in portfolio analysis and how to influence executive decision-making irrespective of your hierarchical level within the organization.

Create nimble development strategies, boost revenues, and extend market exclusivity

Portfolio management of branded medicines stretches from discovery to patent expiration, so it is important to ensure that the transitions from drug discovery to clinical development, registration, and lifecycle management are relatively seamless through a carefully orchestrated ‘push-pull’ mechanism i.e. ‘push’ from discovery and ‘pull’ from commercial. Learn how to create investment options, enable efficient decision-making, analyze ROI, and continuously build equity by maximizing portfolio value under constrained budgetary and human resources.

Build portfolio management excellence

In a rapidly evolving and increasingly competitive business environment, every company must strive to make the best use of its constrained resources by furthering those assets which, despite their inherent risks and uncertainties, are likely to provide sustainable growth. Irrespective of whether a formal group oversees the portfolio management process, executives expect that the best data and information will be presented to them in order for logically consistent and defensible decisions to be made. Explore the different capabilities required to build portfolio management excellence, examine how budgets and human resources can best be utilized, and track the enhanced value of better decisionmaking processes. Finally, create an organizational culture in which every stakeholder sees himself/herself as a contributor to successful enterprise portfolio management.

The Masterclass begins with well-founded theory and quickly moves to practical implementation and executive decision-making based on the trainer’s expertise and experience with 3 major Pharmaceutical and Biotechnology companies (1996-2007) as well as consulting across several industry verticals (2008-present).

Dr. Bayney’s emphasis is on helping organizations move from portfolio value creation to portfolio value maximization by putting in place sequential building blocks to attain protracted excellence in portfolio management.



Further information
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!